Related Experiment Video

Updated: Jun 8, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

The tissue is the issue: personalized medicine for non-small cell lung cancer

Fred R Hirsch1, Murry W Wynes, David R Gandara

  • 1University of Colorado Cancer Center, Aurora, Colorado 80045, USA. Fred.Hirsch@ucdenver.edu

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 8, 2010
PubMed

Insights

Personalized therapy for advanced non-small cell lung cancer (NSCLC) relies on molecular markers. This review focuses on detecting EML4-ALK gene rearrangements for targeted NSCLC treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Advanced non-small cell lung cancer (NSCLC) treatment benefits from personalized approaches.
  • Molecular markers are essential for guiding therapy selection in NSCLC.
  • EML4-ALK gene rearrangements represent a key targetable biomarker.

Purpose of the Study:

  • To review biomarker-driven personalized therapy in NSCLC.
  • To highlight the significance of EML4-ALK gene rearrangement detection.
  • To discuss the clinical application of molecular assays for NSCLC.

Main Methods:

  • Literature review of biomarker-driven therapy in NSCLC.
  • Focus on EML4-ALK gene rearrangement detection methods.
  • Discussion of assay validation and tissue specimen application.

Main Results:

  • Biomarker-driven therapy, particularly targeting EML4-ALK rearrangements, is pivotal for advanced NSCLC.
  • Various molecular assays exist for detecting EML4-ALK.
  • Considerations for assay validation and use across different tissue types are crucial.

Conclusions:

  • Personalized therapy for NSCLC is significantly advanced by molecular marker identification.
  • Effective detection and validation of biomarkers like EML4-ALK are key for clinical success.
  • Tailoring NSCLC treatment based on molecular profiles improves patient outcomes.

More Related Videos

Optimized Preparation of Whole Murine Tumor-Bearing Lung Tissue for Flow Cytometry and Single-Cell RNA-Sequencing06:44

Optimized Preparation of Whole Murine Tumor-Bearing Lung Tissue for Flow Cytometry and Single-Cell RNA-Sequencing

Published on: May 22, 2026

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...